#USA #San Francisco #Hagens Berman #Aardvark Therapeutics #AARD

Aardvark Therapeutics Investors Targeted for Class Action Lawsuit

Investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) have been alerted to a significant opportunity to participate in a class action lawsuit due to perceived losses sustained in the past year. Hagens Berman Sobol Shapiro LLP, a prominent national shareholder rights firm, is seeking individuals who bought Aardvark stock during specific periods, particularly around the company's initial public offering (IPO) on February 13, 2025, through to May 14, 2026.

The Opportunity Ahead

As potential plaintiffs, affected shareholders need to act swiftly. The crucial deadline to file a motion for lead plaintiff status is set for October 13, 2026. Investors are encouraged to reach out to the firm, which has a solid track record in representing such cases, to discuss their legal rights and options for recovery.

Understanding the Lawsuit’s Basis

The allegations underpinning this class action revolve around claims that Aardvark's clinical stage biopharmaceutical product, ARD-101, was marketed with misleading information regarding its safety and development. The company focuses on therapies that target bitter taste receptors, aiming to address hyperphagia associated with Prader-Willi Syndrome (PWS). Legal representatives assert that critical safety information was not disclosed, misleading investors significantly.

Key Allegations Include:

• - ARD-101 exhibited safety issues that were downplayed in communications to investors.
• - During clinical trials, there were unexpected cardiac issues at higher doses that were concealed.
• - Statements made about the safety and efficacy of ARD-101, especially concerning the Phase 3 HERO trial and related studies, overstated the drug's potential and minimized its risks.

The Impact of Recent Developments

On February 27, 2026, Aardvark disclosed a voluntary suspension of its Phase 3 HERO trial due to identified cardiac safety concerns during trials in healthy volunteers. This news had immediate financial repercussions for the company—its stock value plummeted by over 56% in a matter of days. Subsequently, on May 14, 2026, the U.S. Food and Drug Administration (FDA) intervened, instituting a full clinical hold on Aardvark’s IND application for ARD-101, effectively halting all trial activities. This led to a further 32.1% decline in stock price, intensifying investor angst and losses.

What Affected Investors Should Do

If you have experienced financial losses as a result of Aardvark's stock performance, consider reaching out to Hagens Berman. The firm is proactively investigating the claims of misrepresentation and potential negligence involving the company. The potential plaintiffs’ team at Hagens Berman is eager to discuss your eligibility for joining the lawsuit, hence opening doors for possible compensation.

How to Engage with Hagens Berman

Potential investors can submit their information online or contact Hagens Berman directly at [email protected] or via phone at 844-916-0895. Further insights into investors' rights during this turbulent time can be found on the firm’s dedicated webpage for this case. This could be a pivotal moment for investors looking to reclaim losses incurred due to alleged corporate oversight.

Conclusion

The unfolding situation with Aardvark Therapeutics implies significant ramifications for its investors. With pressing deadlines and an escalating need for accountability from corporate entities, shareholders are urged to stay informed and mobilize accordingly. The outcomes of this class action could mark important progress towards corporate responsibility and safeguard investor interests in the face of misleading information.